Selumetinib sulfate is under clinical development by AstraZeneca and currently in Phase II for Neurofibroma. According to GlobalData, Phase II drugs for Neurofibroma have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Selumetinib sulfate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Selumetinib sulfate overview

Selumetinib sulfate (Koselugo / Cocellugo / Coselugo) is a potent anti neoplastic agent. It is formulated as hard gelatin capsules for oral route of administration. Koselugo is indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).

Selumetinib sulfate (ARRY-142886, AZD6244) is under development for the treatment of solid tumors including peripheral nerve sheath tumor (second-line therapy), neurofibromatosis Type I, plexiform neurofibroma, children with recurrent or refractory low-grade gliomas, meningioma, vestibular schwannoma, neuroblastoma, neurofibromatoses type II and acute lymphocytic leukemia. It is administered orally and acts as a mitogen activated protein kinase 1 and 2. It is a new molecular entity (NME).

The drug candidate was also under development for the treatment of differentiated thyroid cancer, advanced biliary tract cancer, metastatic uveal melanoma, recurrent or refractory acute myeloid leukemia, metastatic colorectal cancer, metastatic breast cancer, AIDS-related Kaposi's sarcoma, metastatic pancreatic cancer, metastatic hepatocellular carcinoma, multiple myeloma, relapsed or refractory diffuse large B-cell lymphoma and non-small cell lung cancer, gallbladder cancer, bile duct cancer (Cholangiocarcinoma), neuroblastoma, EGFR mutated non small cell cancer, ovarian or peritoneal cancer and non-Hodgkin lymphoma.

AstraZeneca overview

AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.

For a complete picture of Selumetinib sulfate’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.